Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Inhibikase Therapeutics, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, aiming to raise capital for its development of therapeutics for pulmonary arterial hypertension (PAH) [1][2]. Company Overview - Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing treatments for cardiopulmonary diseases, specifically PAH, which affects approximately 50,000 Americans [5]. - The lead product candidate is IKT-001, a prodrug of imatinib mesylate, targeting the underlying mechanisms of PAH [5]. Offering Details - The company is offering shares of common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1][3]. Underwriters - Jefferies, BofA Securities, and Cantor are the joint book-running managers for the offering, with LifeSci Capital and Oppenheimer & Co. as co-lead managers [2].